SARS-Covid-19 IgG/IgM Antibody Screening Test at Dr. Essa Lab

SARS-Covid-19 IgG/IgM Antibody Screening Test at Dr. Essa Lab

The SARS-Covid-19 IgG/IgM Antibody Screening Test at Dr. Essa Lab is a highly sophisticated serological evaluation designed to detect the presence of specific immunoglobulins (IgG and IgM) produced by the body’s immune system in response to exposure to the SARS-CoV-2 virus. Unlike molecular diagnostic tests such as the Polymerase Chain Reaction (PCR) test, which identify active viral RNA in the respiratory tract, this blood-based serology test evaluates the humoral immune response. By analyzing the serum or plasma of a patient, this screening test provides critical clinical insights into whether an individual has previously contracted the virus, developed an immune response, or mounted antibodies following vaccination. Dr. Essa Laboratory & Diagnostic Centre, a pioneer in diagnostic excellence in Karachi, Pakistan, utilizes advanced immunoassay technologies to deliver highly precise and reliable results for patients seeking to understand their immunological status.

The human immune system responds to a viral pathogen by producing specific proteins called antibodies or immunoglobulins. During the initial phase of an infection, the body synthesizes Immunoglobulin M (IgM) antibodies, which serve as the first line of adaptive defense. These antibodies typically become detectable within 1 to 2 weeks after exposure and gradually decline as the infection resolves. Subsequently, the body produces Immunoglobulin G (IgG) antibodies, which are more specialized and provide long-term immunity. IgG antibodies generally appear later in the course of the infection, often around 2 to 3 weeks post-exposure, and can persist in the bloodstream for several months or even years. The SARS-Covid-19 IgG/IgM Antibody Screening Test at Dr. Essa Lab measures both of these antibody classes, offering a comprehensive overview of the patient’s immunological timeline and helping clinicians differentiate between recent exposure and past, resolved infections.

Understanding your antibody status is of paramount clinical importance. This test is highly valuable for individuals who may have experienced asymptomatic infections, those recovering from persistent post-COVID complications, and individuals wishing to monitor their immune response post-vaccination. By choosing Dr. Essa Lab, patients benefit from a legacy of diagnostic accuracy, state-of-the-art laboratory automation, and expert oversight by qualified consultant pathologists. The test is conducted using standardized blood collection protocols, ensuring maximum patient comfort and safety while maintaining the highest standards of clinical quality.

Clinical Procedure: What to Expect

Patient Preparation

Preparing for the SARS-Covid-19 IgG/IgM Antibody Screening Test at Dr. Essa Lab is simple and straightforward, as it is a non-invasive blood test. Patients are advised to follow these guidelines to ensure an optimal testing experience:

• No Fasting Required: Unlike metabolic or lipid panels, fasting is not required for this serology test. You may eat and drink normally prior to your appointment.
• Hydration: It is highly recommended to drink plenty of water before the test. Proper hydration ensures that your veins are well-filled and easily accessible, making the blood draw smoother and more comfortable.
• Medication Disclosure: Inform the laboratory staff and your physician about any medications you are currently taking, particularly immunosuppressants, corticosteroids, or chemotherapy drugs, as these can suppress the body’s antibody response and affect test interpretation.
• Vaccination History: Be prepared to share your COVID-19 vaccination history, including the dates and types of vaccines received, as this information is crucial for the clinical correlation of your IgG antibody levels.
• Wear Appropriate Clothing: Wear a short-sleeved shirt or clothing with sleeves that can be easily rolled up above the elbow to facilitate easy access to the venipuncture site.

During the Procedure

The blood collection process for the SARS-Covid-19 IgG/IgM Antibody Screening Test at Dr. Essa Lab is performed by highly trained phlebotomists who adhere to strict aseptic techniques and international safety standards. Here is what you can expect during the procedure:

• Patient Identification and Verification: The phlebotomist will first verify your identity, confirm the test requested, and label the collection tubes with your unique patient identification details to prevent any pre-analytical errors.
• Positioning: You will be asked to sit comfortably in a specialized blood-drawing chair. Your arm will be positioned on an armrest to ensure stability during the venipuncture.
• Site Selection and Disinfection: The phlebotomist will inspect your arm, typically the antecubital fossa (the crease of the elbow), to locate a suitable vein. Once selected, the area will be thoroughly cleansed with an antiseptic swab (70% isopropyl alcohol) and allowed to air dry to prevent contamination.
• Tourniquet Application: A soft elastic tourniquet will be tied around your upper arm to temporarily restrict venous blood flow, making the veins more prominent and easier to access.
• Venipuncture: A sterile, single-use needle attached to a vacuum collection tube (typically a gold-top serum separator tube or a red-top tube) will be gently inserted into the vein. You may feel a brief, mild pinch or prick as the needle enters the skin.
• Sample Collection: The required volume of blood (usually 3 to 5 milliliters) will be drawn into the tube. Once the collection is complete, the tourniquet is released, and the needle is carefully withdrawn.
• Post-Puncture Care: The phlebotomist will immediately apply a sterile cotton ball or gauze pad to the puncture site and ask you to apply gentle pressure for a few minutes to promote hemostasis and prevent bruising. A small adhesive bandage will then be applied over the site.
• Duration and Safety: The entire blood draw process takes less than five minutes. All materials used, including needles and syringes, are disposed of immediately in designated biohazard containers to maintain a sterile and safe environment.

When is a SARS-Covid-19 IgG/IgM Antibody Screening Test Performed?

Assessment of Prior Asymptomatic or Undiagnosed Infection

Many individuals who contract SARS-CoV-2 experience mild symptoms or remain completely asymptomatic throughout the course of the infection. Because they did not feel ill enough to seek a PCR test during the active phase, they may remain unaware of their exposure. The SARS-Covid-19 IgG/IgM Antibody Screening Test is performed to determine if an individual has had a past, undetected infection, providing clarity regarding their exposure history and helping them understand if their immune system has already encountered the virus.

Evaluation of Immune Response Post-Vaccination

With the widespread administration of COVID-19 vaccines, many patients and healthcare providers utilize antibody screening to assess the body’s humoral response to the vaccine. This test helps verify whether the vaccine has successfully stimulated the production of protective IgG antibodies. It is particularly useful for individuals with underlying health conditions or those who are immunocompromised, as it helps determine if they have mounted an adequate immune response following their vaccination regimen.

Investigating Post-COVID Complications and Long COVID

Some patients experience persistent, unexplained symptoms weeks or months after recovering from a viral illness, a condition often referred to as “Long COVID” or Post-Acute Sequelae of SARS-CoV-2 (PASC). In cases where a patient did not have a confirmed PCR test during their initial illness, physicians request an antibody screening test to confirm whether the patient had a prior SARS-CoV-2 infection. Establishing this link is essential for diagnosing post-viral syndromes and tailoring appropriate rehabilitative care.

Screening for Multisystem Inflammatory Syndrome (MIS)

Multisystem Inflammatory Syndrome in Children (MIS-C) and Adults (MIS-A) is a rare but serious inflammatory condition that can develop several weeks after a SARS-CoV-2 infection. Patients presenting with symptoms of MIS often test negative on active viral PCR tests because the acute infection has resolved. Clinicians perform the IgG/IgM antibody screening test to confirm a recent prior infection, which is a key diagnostic criterion for this inflammatory syndrome, allowing for prompt and life-saving therapeutic intervention.

Epidemiological Surveillance and Workplace Safety

Public health organizations, corporate entities, and healthcare facilities perform antibody screening on a broader scale to conduct epidemiological surveillance. By understanding the prevalence of antibodies within a specific population, community, or workforce, decision-makers can assess herd immunity levels, evaluate the effectiveness of public health interventions, and implement informed safety protocols to protect employees and patients in high-risk environments.

What Does a SARS-Covid-19 IgG/IgM Antibody Screening Test Detect?

The SARS-Covid-19 IgG/IgM Antibody Screening Test at Dr. Essa Lab is designed to detect and differentiate specific immunological markers. The clinical findings and parameters evaluated during this screening include:

• Immunoglobulin M (IgM) Reactivity: Detects the presence of early-phase antibodies, indicating a recent exposure or active phase of infection.
• Immunoglobulin G (IgG) Reactivity: Identifies long-term antibodies, indicating a past resolved infection or vaccine-induced immunity.
• Seroconversion Status: Determines whether the patient’s immune system has transitioned from antibody-negative to antibody-positive.
• Anti-Spike (S) Protein Antibodies: Evaluates antibodies directed against the spike protein of the virus, commonly produced after both vaccination and natural infection.
• Anti-Nucleocapsid (N) Protein Antibodies: Detects antibodies against the internal viral nucleocapsid, typically indicating exposure to the actual virus rather than vaccination (depending on the vaccine type).
• Early Window Period Identification: Recognizes cases where a patient is infected but has not yet developed detectable antibody levels.
• Active Recovery Phase: Indicated by the simultaneous presence of both IgM and IgG antibodies.
• Long-Term Humoral Immunity: Indicated by isolated IgG positivity with negative IgM.
• Absence of Immune Response: Indicated by double-negative (IgG and IgM negative) results, suggesting no prior exposure or failure to mount an immune response.
• Waning Immunity: Detects declining antibody titers over extended periods post-infection or post-vaccination.
• Cross-Reactive Antibodies: Identifies potential false-positive signals caused by pre-existing antibodies from other seasonal coronaviruses.
• Immunosuppression Impact: Highlights a lack of antibody production in patients undergoing immunosuppressive therapies despite confirmed prior infection.
• Maternal Antibody Transfer: Detects passive immunity in newborns whose mothers were vaccinated or infected during pregnancy.
• Anamnestic Response: Evaluates rapid antibody surges following a booster dose or re-exposure.
• Hybrid Immunity: Assesses robust antibody profiles resulting from a combination of natural infection and vaccination.
• Specimen Quality Check: Ensures the serum sample is free from severe hemolysis, lipemia, or icterus, which could interfere with optical readings.
• Assay Control Validation: Verifies that the internal laboratory control parameters are met for accurate diagnostic reporting.
• Quantitative Antibody Levels: Measures the concentration of antibodies (if using quantitative platforms) to track immune strength over time.
• Qualitative Screening Index: Provides a cut-off index (COI) to determine positive, negative, or equivocal results.
• Post-Viral Syndrome Correlation: Helps correlate unexplained inflammatory symptoms with a confirmed biological footprint of past COVID-19.

Turnaround Time and Report Access at Dr. Essa Lab

Dr. Essa Laboratory & Diagnostic Centre is committed to providing rapid, accurate, and accessible diagnostic reporting. For the SARS-Covid-19 IgG/IgM Antibody Screening Test, the standard turnaround time is typically within 12 to 24 hours from the time of sample collection. This rapid processing ensures that patients and referring physicians can make timely clinical decisions without unnecessary delay.

Once the analysis is completed and verified by our consultant pathologists, patients receive an automated SMS notification containing a direct link to download their reports. Reports can also be accessed securely through the official Dr. Essa Lab website by entering the unique lab ID and patient credentials. For added convenience, physical copies of the report can be collected from any of our conveniently located diagnostic centers across Karachi, or delivered directly to your home through our dedicated home dispatch service.

SARS-Covid-19 IgG/IgM Antibody Screening Test Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
SARS-CoV-2 IgM Antibodies	Non-reactive (Negative)	Reactive (Positive) – Indicates recent or active phase of infection.
SARS-CoV-2 IgG Antibodies	Non-reactive (Negative)	Reactive (Positive) – Indicates past infection, vaccination, or late-stage active infection.
Anti-Spike (S) IgG Antibodies	Non-reactive (Negative)	Reactive (Positive) – Suggests immune response from vaccination or natural exposure.
Anti-Nucleocapsid (N) IgG Antibodies	Non-reactive (Negative)	Reactive (Positive) – Suggests prior natural infection with the wild-type virus.
Specimen Integrity (Serum Index)	Clear, non-hemolyzed, non-lipemic sample	Hemolyzed, lipemic, or icteric sample (may require a repeat blood draw).
Antibody Cut-off Index (COI)	COI < 1.0 (Negative)	COI ≥ 1.0 (Positive) – Confirms presence of detectable antibodies.
Internal Assay Control Line	Visible and validated	Absent or faint control line (Invalid run, requires immediate retesting).
Rheumatoid Factor / Cross-reactants	Absent (No analytical interference)	Present (Can cause false-positive IgM results due to non-specific binding).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for SARS-Covid-19 IgG/IgM Antibody Screening Test?

• Legacy of Trust: Serving patients since 1987 with an unwavering commitment to diagnostic accuracy and clinical excellence.
• ISO Certified Quality: Operating under strict international quality management standards to ensure highly reliable and reproducible test results.
• Expert Pathologists: All serological assays are supervised, reviewed, and signed off by highly qualified consultant pathologists and microbiologists.
• Advanced Technology: Utilizing state-of-the-art fully automated chemiluminescent immunoassay (CLIA) and ELISA platforms for superior sensitivity and specificity.
• Convenient Home Sample Collection: Offering professional phlebotomy services at your doorstep, allowing you to get tested in the comfort of your home.
• Extensive Branch Network: Conveniently located collection centers across Karachi and other major cities, ensuring easy accessibility for all patients.
• Secure Online Reports: Quick and hassle-free access to your diagnostic reports through our user-friendly online portal and instant SMS alerts.
• Patient-Centric Care: Dedicated customer support and compassionate staff focused on providing a seamless, comfortable, and professional diagnostic experience.